personalized peptide cancer vaccine

A personalized peptide cancer vaccine is a form of immunotherapy designed to elicit a T-cell response against patient-specific tumor neoantigens. These vaccines are manufactured by identifying unique mutations within a patient's tumor through genomic sequencing, predicting which mutated peptides (neoantigens) will most effectively bind to the patient's HLA molecules, and then synthesizing those peptides for administration. In the context of the trial at Renji Hospital (ChiCTR2400083167), this vaccine is being evaluated in combination with a PD-1 inhibitor for the treatment of late-stage pancreatic ductal adenocarcinoma (PDAC). The goal is to broaden the repertoire of tumor-specific T cells and overcome the immunosuppressive microenvironment of pancreatic tumors.

Other names

Personalized peptide vaccinePersonalized neoantigen peptide vaccinePersonalized cancer vaccine